Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.03 | 0.93 | 1.72 | -0.26 |
| FCF Yield | 0.00% | 0.00% | 0.00% | -9.49% |
| EV / EBITDA | 22.43 | 23.36 | 14.09 | 14.43 |
| Quality | ||||
| ROIC | 0.99% | 1.44% | 0.43% | 0.47% |
| Gross Margin | 19.66% | 16.12% | 16.61% | 17.88% |
| Cash Conversion Ratio | – | – | – | 3.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.06% | 3.94% | 3.19% | 2.21% |
| Free Cash Flow Growth | 0.00% | 0.00% | 100.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 4.70 | 5.70 | 4.86 | 4.83 |
| Interest Coverage | 33.27 | 19.79 | 11.68 | 18.29 |
| Efficiency | ||||
| Inventory Turnover | 0.58 | 0.64 | 0.48 | 0.46 |
| Cash Conversion Cycle | 172.57 | 207.46 | 239.03 | 250.04 |